• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

19.18 -0.07 (-0.36%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,429,166
Open 19.28
Bid (Size) 18.90 (500)
Ask (Size) 19.90 (400)
Prev. Close 19.25
Today's Range 18.94 - 19.39
52wk Range 9.750 - 21.18
Shares Outstanding 1,000
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
1 Profitable Stock for Long-Term Investors and 2 Facing Headwinds
October 13, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
3 Overrated Stocks We Think Twice About
October 09, 2026
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne... 
Via StockStory

Performance

52-Week Range 9.4% below 52-week high
19.18
9.7552W Low 21.1852W High
1 Week 5.4% below 1-week high
18.791W Low 20.281W High

Amneal Pharmaceuticals, Inc. - Class A Common Stock (AMRX) traded between $9.75 and $21.18 over the past 52 weeks and last traded at $19.18, 9.4% below its 52-week high. Over the past week it ranged between $18.79 and $20.28.

Past 12 Months
-4.2%
+6.1%
+7.5%
+37.9%
+51.5%
+94.3%
1W -$0.85
1M +$1.10
3M +$1.33
6M +$5.27
YTD +$6.52
1Y +$9.31

AMRX was +94.3% over the past year, +37.9% over six months, +51.5% year to date, -4.2% in the last week.

12 Months vs Market
AMRX
+94.3%
DIA
+13.0%
SPY
+15.5%
QQQ
+18.3%
IWM
+10.4%

Over the past 12 months AMRX returned +94.3% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +10.4%.

Volume & Liquidity 0.99× 3-mo avg
Today 2,429,166 3-mo avg 2.5M
1W
4.1M
1M
3.8M
3M
2.5M
6M
2.2M
YTD
2.3M
1Y
2.2M

AMRX most recently traded 2,429,166 shares against a 3-month average daily volume of 2.5M.

More News

Read More
News headline image
Amneal to Report Third Quarter 2026 Results on November 3, 2026
October 08, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 Low-Volatility Stocks with Open Questions
October 05, 2026
Via StockStory
Amneal Pharmaceuticals (NASDAQ:AMRX) Soars on Q2 Earnings Beat and Raised Guidance ↗
July 30, 2026
Via Chartmill
Topics Earnings
News headline image
Why Is Amneal (AMRX) Stock Rocketing Higher Today
September 21, 2026
Via StockStory
News headline image
Amneal Announces FDA Approval and Launch of Lanreotide Injection
September 18, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
September 18, 2026
Via StockStory
News headline image
Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX)
August 30, 2026
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Stock Under $50 with Solid Fundamentals and 2 Facing Challenges
August 26, 2026
Via StockStory
News headline image
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm
August 19, 2026
From Kaskela Law
Via Business Wire
News headline image
1 Russell 2000 Stock with Exciting Potential and 2 We Ignore
August 19, 2026
Via StockStory
News headline image
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
August 10, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
1 Healthcare Stock Worth Your Attention and 2 We Ignore
August 07, 2026
Via StockStory
News headline image
5 Insightful Analyst Questions From Amneal’s Q2 Earnings Call
August 06, 2026
Via StockStory
Topics Earnings World Trade
News headline image
AMRX Q2 Deep Dive: Diversified Product Mix and Biosimilars Strategy Shape Guidance
July 31, 2026
Via StockStory
News headline image
Amneal (AMRX) Q2 2026 Earnings Call Transcript ↗
July 30, 2026
Via The Motley Fool
Topics Earnings
News headline image
Amneal Pharmaceuticals Q2 Earnings Call Highlights ↗
July 30, 2026
Via MarketBeat
Topics Earnings
News headline image
Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9%
July 30, 2026
Via StockStory
News headline image
Amneal Reports Second Quarter 2026 Financial Results
July 30, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal (AMRX) Reports Q2: Everything You Need To Know Ahead Of Earnings
July 28, 2026
Via StockStory
News headline image
Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1
July 27, 2026
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm
July 23, 2026
From Kaskela Law LLC
Via Business Wire
News headline image
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
July 17, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 Reasons AMRX is Risky and 1 Stock to Buy Instead
July 15, 2026
Via StockStory
Topics Stocks

Frequently Asked Questions

Is Amneal Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Amneal Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Amneal Pharmaceuticals, Inc. - Class A Common Stock trade on?
Amneal Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock is AMRX on the Nasdaq Stock Market
What is the current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 19.18
When was Amneal Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Amneal Pharmaceuticals, Inc. - Class A Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 19.18K
How many shares of Amneal Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Amneal Pharmaceuticals, Inc. - Class A Common Stock has 19K shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap